739 Stock Overview
Apeloa Pharmaceutical Co.,Ltd provides raw materials and intermediates to various pharmaceutical factories in China and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 1/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 4/6 |
Apeloa Pharmaceutical Co.,Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥14.11 |
52 Week High | CN¥21.15 |
52 Week Low | CN¥10.66 |
Beta | 0.059 |
1 Month Change | 9.72% |
3 Month Change | 17.78% |
1 Year Change | -31.74% |
3 Year Change | -54.63% |
5 Year Change | 45.46% |
Change since IPO | 78.83% |
Recent News & Updates
Recent updates
Shareholder Returns
739 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | 4.6% | 5.7% | 4.2% |
1Y | -31.7% | -11.0% | -13.2% |
Return vs Industry: 000739 underperformed the CN Pharmaceuticals industry which returned -11% over the past year.
Return vs Market: 000739 underperformed the CN Market which returned -13.2% over the past year.
Price Volatility
739 volatility | |
---|---|
739 Average Weekly Movement | 6.1% |
Pharmaceuticals Industry Average Movement | 7.7% |
Market Average Movement | 8.7% |
10% most volatile stocks in CN Market | 12.6% |
10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 000739 has not had significant price volatility in the past 3 months.
Volatility Over Time: 000739's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1989 | 7,208 | Xinliang Xu | www.apeloa.com |
Apeloa Pharmaceutical Co.,Ltd provides raw materials and intermediates to various pharmaceutical factories in China and internationally. The company offers preparation products, including cardio-cerebrovascular, anti-infection, anti-tumor, anti-viral, and special drugs. It offers its products under the Tianliwei, Beshin, Yosemade, Jutai, and other brands.
Apeloa Pharmaceutical Co.,Ltd Fundamentals Summary
739 fundamental statistics | |
---|---|
Market cap | CN¥16.50b |
Earnings (TTM) | CN¥1.06b |
Revenue (TTM) | CN¥11.59b |
15.6x
P/E Ratio1.4x
P/S RatioIs 739 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
739 income statement (TTM) | |
---|---|
Revenue | CN¥11.59b |
Cost of Revenue | CN¥8.83b |
Gross Profit | CN¥2.76b |
Other Expenses | CN¥1.70b |
Earnings | CN¥1.06b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.91 |
Gross Margin | 23.81% |
Net Profit Margin | 9.15% |
Debt/Equity Ratio | 14.9% |
How did 739 perform over the long term?
See historical performance and comparison